Clinical case of psoriasis in an HIV-positive patient
- 作者: Kleymenova V.1, Krinitsyna Y.1,2, Pakhomova V.1
-
隶属关系:
- Novosibirsk Regional Clinical Dermatovenerologic Dispensary
- Federal Research Center of Fundamental and Translational Medicine
- 期: 卷 26, 编号 3 (2023)
- 页面: 235-242
- 栏目: DERMATOLOGY
- URL: https://journals.rcsi.science/1560-9588/article/view/132611
- DOI: https://doi.org/10.17816/dv321342
- ID: 132611
如何引用文章
详细
Modern ideas about psoriasis are becoming wider, while the incidence of this dermatosis is increasing every year. Psoriasis does not seem to be just a skin pathological process, since the basis of this disease is the development of chronic systemic immune inflammation resulting from the launch of a complex cascade of immune reactions with impaired activity of T-lymphocytes and the production of various pro-inflammatory cytokines and chemokines.
The course of psoriatic disease has its own characteristics in a patient with human immunodeficiency virus. The peculiarities of the course of psoriasis in a patient with human immunodeficiency virus require a personalized approach in therapy.
This article describes a clinical case of psoriasis in a patient with newly diagnosed human immunodeficiency virus. The stages of the diagnostic search for HIV infection are described. To confirm the diagnosis of psoriasis, a pathohistological examination of a skin biopsy was performed, as well as additional laboratory and instrumental studies. The main features of the course of psoriatic disease in an HIV-positive patient are demonstrated: a combination of several clinical forms of the disease, severe severity, lack of necessary positive dynamics against the background of external and basic anti-inflammatory forms of therapy.
作者简介
Valeriya Kleymenova
Novosibirsk Regional Clinical Dermatovenerologic Dispensary
编辑信件的主要联系方式.
Email: l120595444l@gmail.com
ORCID iD: 0000-0002-0948-2419
俄罗斯联邦, Novosibirsk
Yulia Krinitsyna
Novosibirsk Regional Clinical Dermatovenerologic Dispensary; Federal Research Center of Fundamental and Translational Medicine
Email: julia407@yandex.ru
ORCID iD: 0000-0002-9383-0745
SPIN 代码: 5925-9031
MD, Dr. Sci. (Med.), Professor
俄罗斯联邦, Novosibirsk; NovosibirskVera Pakhomova
Novosibirsk Regional Clinical Dermatovenerologic Dispensary
Email: vera9037@mail.ru
ORCID iD: 0000-0002-0379-7823
俄罗斯联邦, Novosibirsk
参考
- Kubanov АА, Bogdanova EV. Epidemiology of psoriasis among the elderly population and volume of specialized medical care provided to patients with psoriasis in the Russian Federation in 2010–2019. Vestnik Dermatologii i Venerologii. 2020;96(5):7–18. (In Russ). doi: 10.25208/vdv1171-2020-96-5-07-18
- Potekaev NN, Zhukova OV, Artemyeva SI. Psoriasis: A personalized approach to therapy. The preferred choice of systemic agents considering comorbid pathologies. Meditsinskiy sovet. 2020;(12):28–34. (In Russ). doi: 10.21518/2079-701X-2020-12-28-34
- Lynch M, Ahern T, Sweeney CM, et al. Adipokines, psoriasis, systemic inflammation, and endothelial dysfunction. Int J Dermatol. 2017;56(11):1103–1118. doi: 10.1111/ijd.13699
- Alpalhão M, Borges-Costa J, Filipe P. Psoriasis in HIV infection: An update. Int J STD AIDS. 2019;30(6):596–604. doi: 10.1177/0956462419827673
- Gong J, Weiwei W, Liguo Q, et al. Interleukin-17A inhibitor secukinumab treatment in HIV-POSITIVE psoriasis patient: A case report. Clin Cosmetic Investigational Dermatol. 2022;2949–2956. doi: 10.2147/CCID.S395348
- Ceccarelli M, Rullo VE, Vaccaro M, et al. HIV-associated psoriasis: Epidemiology, pathogenesis, and management. Dermatologic Therapy. 2019;32(2):e12806. doi: 10.1111/dth.12806
- Chaiyabutr C, Jiamton S, Silpa-Archa N, et al. Retrospective study of psoriasis in people living with HIV: Thailand’s experience. J Dermatol. 2022;49(6):607–614. doi: 10.1111/1346-8138.16352
- Morar N, Willis-Owen SA, Maurer T, et al. HIV-associated psoriasis: Pathogenesis, clinical features, and management. Lancet Inf Dis. 2010;10(7):470–478. doi: 10.1016/S1473-3099(10)70101-8
- Arbune M, Arbune MM, Niculetet E, et al. Therapeutic challenges of psoriasis in the HIV-infected patient: A case report. Exp Therapeutic Med. 2022;23(2):175. doi: 10.3892/etm.2021.11098
- Plachouri KM, Georgiou S. Challenges in the treatment of psoriasis with biologics: Vaccination, history of malignancy, human immunodeficiency virus (HIV) infection, and pediatric psoriasis. Int J Dermatol. 2019;58(9):1008–1013. doi: 10.1111/ijd.14436
- Teh YC, Robinson S, Tan WC, et al. Psoriasis patients with human immunodeficiency virus infection: Data from the Malaysian psoriasis registry. Malaysian J Dermatol. 2021;46:1–10.
- Myers B, Thibodeaux Q, Reddy V, et al. Biologic treatment of 4 HIV-positive patients: A case series and literature review. J Psoriasis Psoriatic Arthritis. 2021;6(1):19–26. doi: 10.1177/2475530320954279
- Kaushik SB, Lebwohl MG. Psoriasis: Which therapy for which patient. Focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43–53. doi: 10.1016/j.jaad.2018.06.056
- Naovarat BS, Salazar G, Ishimori M, et al. Biological treatment usage in patients with HIV and rheumatic disease, 2003–2021: Long-term safety and follow-up. RMD Open. 2022;8(2):e002282. doi: 10.1136/rmdopen-2022-002282
- Myers B, Thibodeaux Q, Reddy V, et al. Biologic treatment of 4 HIV-positive patients: A case series and literature review. J Psoriasis Psoriatic Arthritis. 2021;6(1):19–26. doi: 10.I177/2475530320954279